EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation

Ruwani K Suraweera iD, Kirsten M Spann, Emad L Izake iD, Timothy J Wells, Xiaodong Wang iD, Nazrul Islam iD

Pharmaceutics · 22.11.2024 · 16 (12) · 1506

DOI: 10.3390/pharmaceutics16121506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.11.2024. Verfasst von Ruwani K Suraweera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Discipline, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study explores the development and characterization of spray-dried composite microparticles consisting of levofloxacin (LVX, a broad-spectrum antibiotic), and ambroxol (AMB, a mucolytic agent that has antibacterial and antibiofilm properties), for the intended application of the drug against lower respiratory tract infections (LRTIs).

Methods

A range of LVX to AMB mass ratios (1:1, 1:0.5, and 1:0.25) were prepared, with and without the use of the dispersibility enhancer leucine (LEU), and spray-dried following pre-optimized parameters to achieve the required particle size (1–5 µm) and flow properties. The formulations were characterized by attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), and a thermogravimetric analysis (TGA). The in vitro aerosolization performance of the new formulation was evaluated with a twin-stage impinger (TSI) at a flow rate of 60 ± 5 L/min. Using a validated RP-HPLC method, LVX and AMB were quantitatively determined.

Results

The combined spray-dried LVX, AMB, and LEU particles were spherically shaped with sizes ranging from 1.9 to 2.9 µm, thus complying with the size requirements for effective deep lung deposition. The dispersibility enhancer leucine produced a high yield and enhanced the flow properties and aerosolization characteristics of the spray-dried formulations. The LVX to AMB mass ratios showed a remarkable impact on the aerosolization properties, with the LVX to AMB 1:1 mass ratio demonstrating the best flow and FPFs for both drugs. There must be a balanced ratio of these components for spray drying the composite particles to obtain composite particles of the required size and with the appropriate flow property. The addition of 5% of LEU significantly (p < 0.005) improved the FPF of all the formulations, probably by enhancing the surface hydrophobicity of the composite particles.

Conclusions

The spray-dried combined antibiotics formulation has a strong potential for efficient lung delivery intended for the management of LRTIs.

Schlagwörter

Stichwörter der Autor:innen

ambroxoldry powder inhaler formulationslevofloxacinpulmonary drug deliveryspray drying

Autor:innen und Institutionen

  • Pharmacy Discipline, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
  • Centre for Immunology and Infection Control (CIIC), Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
  • School of Chemistry and Physics, Faculty of Science, Queensland University of Technology, Brisbane, QLD 4000, Australia.
  • Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4102, Australia.
  • Central Analytical Research Facility, Queensland University of Technology, Gardens Point Campus, Brisbane, QLD 4000, Australia.

ORCID-Profile: Ruwani K Suraweera, Emad L Izake, Xiaodong Wang, Nazrul Islam

Zitieren

APA

Suraweera, R. K., Spann, K. M., Izake, E. L., Wells, T. J., Wang, X., & Islam, N. (2024). Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation. Pharmaceutics, 16(12), 1506. https://doi.org/10.3390/pharmaceutics16121506

Vancouver

Suraweera RK, Spann KM, Izake EL, Wells TJ, Wang X, Islam N. Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation. Pharmaceutics. 2024;16(12):1506. doi:10.3390/pharmaceutics16121506

BibTeX
@article{Suraweera2024,
  author = {Suraweera, Ruwani K and Spann, Kirsten M and Izake, Emad L and Wells, Timothy J and Wang, Xiaodong and Islam, Nazrul},
  title = {Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {1506},
  doi = {10.3390/pharmaceutics16121506}
}
Kostenlos starten →